Carretero OA. Aldosterone sensitizes connecting tubule glomerular feedback via the aldosterone receptor GPR30. Am J Physiol Renal Physiol 307: F427-F434, 2014. First published June 25, 2014 doi:10.1152/ajprenal.00072.2014.-Increasing Na delivery to epithelial Na channels (ENaC) in the connecting tubule (CNT) dilates the afferent arteriole (Af-Art), a process we call connecting tubule glomerular feedback (CTGF). We hypothesize that aldosterone sensitizes CTGF via a nongenomic mechanism that stimulates CNT ENaC via the aldosterone receptor GPR30. Rabbit AfArts and their adherent CNTs were microdissected and simultaneously perfused. Two consecutive CTGF curves were elicited by increasing luminal NaCl in the CNT. During the control period, the concentration of NaCl that elicited a half-maximal response (EC50) was 37.0 Ϯ 2.0 mmol/l; addition of aldosterone 10 Ϫ8 mol/l to the CNT lumen caused a left-shift (decrease) in EC 50 to 19.3 Ϯ 1.3 mmol/l (P ϭ 0.001 vs. control; n ϭ 6). Neither the transcription inhibitor actinomycin D nor the translation inhibitor cycloheximide prevented the effect of aldosterone (control EC50 ϭ 34.7 Ϯ 1.9 mmol/l; aldosteroneϩactinomycin D EC50 ϭ 22.6 Ϯ 1.6 mmol/l; P Ͻ 0.001 and control EC50 ϭ 32.4 Ϯ 4.3 mmol/l; aldosteroneϩcycloheximide EC50 ϭ 17.4 Ϯ 3.3 mmol/l; P Ͻ 0.001). The aldosterone antagonist eplerenone prevented the sensitization of CTGF by aldosterone (control EC50 ϭ 33.2 Ϯ 1.7 mmol/l; aldosteroneϩeplerenone EC50 ϭ 33.5 Ϯ 1.3 mmol/l; n ϭ 7). The GPR30 receptor blocker G-36 blocked the sensitization of CTGF by aldosterone (aldosterone EC50 ϭ 16.5 Ϯ 1.9 mmol/l; aldosteroneϩG-36 EC50 ϭ 29.0 Ϯ 2.1 mmol/l; n ϭ 7; P Ͻ 0.001). Finally, we found that the sensitization of CTGF by aldosterone was mediated, at least in part, by the sodium/hydrogen exchanger (NHE). We conclude that aldosterone in the CNT lumen sensitizes CTGF via a nongenomic effect involving GPR30 receptors and NHE. Sensitized CTGF induced by aldosterone may contribute to renal damage by increasing Af-Art dilation and glomerular capillary pressure (glomerular barotrauma).
termed connecting tubule glomerular feedback (CTGF) (32, 34) . CTGF is initiated by increases in Na concentration in the CNT lumen and results in dilation of the Af-Art. These physiological mechanisms regulate glomerular hemodynamics and electrolyte balance.
Aldosterone acts in the CNT and other nephron segments to regulate electrolyte homeostasis. There is now increasing evidence that in animal models with high aldosterone levels, as well as in patients with primary aldosteronism, aldosterone causes glomerular hypertension/hyperfiltration leading to glomerulosclerosis (9, 35) . Although the mechanisms by which these detrimental effects of aldosterone occur remain unknown, it may be that aldosterone sensitizes CTGF, which dilates the Af-Art, thus leading to an elevation in glomerular capillary pressure and glomerular damage.
Historically it was thought that aldosterone acted solely via the classic genomic mechanism involving intracellular binding to the mineralocorticoid receptor (MR), thereby affecting transcription and protein synthesis; however, faster actions were also described that could not be explained by genomic mechanisms (3) . Recently, a G protein-coupled receptor, GPR30, was shown to be involved in rapid actions of aldosterone in vascular smooth muscle cells (18) , and in the nucleus ambiguous (4) that occur as fast as within 2 min.
In the present study, we hypothesize that aldosterone in the CNT lumen sensitizes CTGF acutely via a nongenomic mechanism by stimulating GPR30 receptors. We tested this hypothesis using a technique developed by us in which we simultaneously perfuse a microdissected rabbit Af-Art and its adherent CNT, thus avoiding the confounding influence of the multiple systems that regulate the renal microcirculation.
METHODS
New Zealand White male rabbits weighing 1.5-2 kg (Myrtle's Rabbitry) were given standard chow (Ralston Purina, St. Louis, MO) and tap water ad libitum and anesthetized with ketamine (50 mg/kg im), xylazine (10 mg/kg im), and pentobarbital sodium (25 mg/kg iv). All protocols were approved by Henry Ford Health System's Institutional Animal Care and Use Committee and adhered to APS's Guiding Principles in the Care and Use of Animals, including the provision to comply with the National Institutes of Health Guide for the Care and Use of Laboratory Animals. We used rabbits because their CNTs are well demarcated and microdissection of the CNT and attached Af-Art is easier than in rats or mice. To isolate and microperfuse the Af-Art and CNT, we used methods similar to those described previously (30, 34) . The kidneys were sliced along the corticomedullary axis and slices were placed in ice-cold minimum essential medium (MEM; GIBCO Laboratories, Grand Island, NY) containing 5% BSA (Sigma, St. Louis, MO). A single superficial Af-Art with its intact glomerulus was dissected together with the adherent CNT. The microdissected complex was transferred to a temperature-regulated perfusion chamber mounted on an inverted microscope with Hoffmann modulation. Both the Af-Art and CNT were cannulated with an array of concentric glass pipettes as described previously (5, 19) . The Af-Art was perfused with MEM containing 5% BSA gassed with room air. Intraluminal pressure was measured by Landis' technique and maintained at 60 mmHg. The CNT perfusion solution contained (in mmol/l) 4 KHCO 3, 10 HEPES, 0.5 Na acetate, 0.5 Na lactate, 0.5 K2HPO4, 1.2 MgSO4, 1 CaCO3, and 5.5 glucose, adding 1 mol/l NaCl to achieve the desired final NaCl concentration. Tubular perfusion was controlled by use of a syringe microperfusion pump (Harvard Apparatus) set to 20 nl/min (calibration checked to be Ϸ20 nl/min), which is within the range of physiological flow rates (15, 21) . The bath was superfused with MEM containing 0.15% BSA at a rate of 1 ml/min.
Microdissection and cannulation of the Af-Art and CNT were completed within 90 min at 8°C, after which the temperature was gradually raised to 37°C. Once it was stable, a 30-min equilibration period was allowed before any measurements were taken. Since isolated arteries have little or no tone and our preliminary studies showed that increasing NaCl in the CNT perfusate caused only modest dilation of the Af-Art unless it was preconstricted, we performed all CTGF experiments with Af-Arts preconstricted with norepinephrine (NE; 2-5 ϫ 10 Ϫ7 mol/l). In each experiment, two consecutive concentration-response curves were generated by increasing luminal NaCl in the CNT from 0 to 5, 10, 20, 40, and 80 mmol/l (each NaCl concentration was maintained for 5 min). Af-Art diameter was measured in the region of maximal response to NE at three sites 3-5 m apart and expressed as the average of these three measurements. Diameter was recorded at 5-s intervals with a video camera and measured with a computer equipped with Metavue image analysis software (MDS Analytical Technologies, Toronto, Ontario, Canada).
All drugs were added to the lumen of the CNT. The concentrations of the various reagents we used were based on previous publications: aldosterone (12) , eplerenone (12) , cycloheximide (23) , actinomycin D (23), and G36 (7) . Actinomycin D and cycloheximide were added to the nephron and we waited for 10 min before changing luminal NaCl concentration, based on previous literature showing inhibition of genomic effects (36, 37) . G-36 was purchased from Azano Pharmaceuticals (Albuquerque, NM); all other chemicals were purchased from Sigma.
Statistics. Values are expressed as means Ϯ SE. Paired t-tests were used to compare CTGF (⌬Af-Art diameter) between the control and experimental periods. Hochberg's step-up procedure was used to adjust the P values for multiple comparisons. We found that the main effect of aldosterone was to sensitize CTGF, rather than to affect the maximal vasodilation that can be achieved in the Af-Art, thus we analyzed the data by comparing the concentration of NaCl in the CNT perfusate needed to achieve half of the maximal response (EC 50). In other words, a decrease in EC50 indicates a left-shift in the CTGF curve. EC50 values were determined by SAS probit analysis (Statistical Analysis system, SAS Institute, Cary, NC). In experiments where one of the curves was flat, EC 50 was not calculated.
RESULTS
To show that the CTGF response remains stable over time, we performed two consecutive concentration-response curves to 0, 5, 10, 20, 40, and 80 mmol/l of NaCl in the CNT lumen. NE was administered to the Af-Art to cause an ϳ50% decrease in its diameter when the attached CNT was perfused with 0 mmol/l NaCl. Increasing NaCl concentration in the CNT caused the Af-Art to relax in a concentration-dependent manner, restoring basal diameter at 80 mmol/l NaCl. We then returned CNT luminal NaCl concentration to zero and repeated the stepwise increase in NaCl concentration. The concentration of NaCl in the CNT perfusate needed to achieve the EC 50 was 32.3 Ϯ 1.4 mmol/l in the first curve and 30.9 Ϯ 1.0 mmol/l in the second. Thus, the two curves were similar, confirming that the CTGF response is stable over time (Fig. 1A) .
To study the effect of intratubular aldosterone on CTGF, we repeated the above described experiment, but added 10 Ϫ8 mol/l aldosterone to the CNT perfusate during the second doseresponse curve. When the CNT was perfused with 0 mmol/l NaCl, aldosterone did not affect Af-Art diameter. However, when CNT NaCl concentration was increased in the presence of aldosterone, CTGF-induced dilation of the Af-Art was sensitized, i.e., the curve was shifted to the left (control EC 50 37.0 Ϯ 2.0 mmol/l, aldosterone EC 50 19.3 Ϯ 1.3 mmol/l, P ϭ 0.001, Fig. 1B ). These data demonstrate that intratubular aldosterone sensitizes the CTGF response.
To study whether the effect of aldosterone on CTGF was genomic or nongenomic, we perfused the CNT during the second dose-response curve with both aldosterone and the transcription inhibitor actinomycin D 5 ϫ 10 Ϫ6 mol/l. Aldo- sterone sensitized CTGF in the presence of actinomycin D (control EC 50 34.7 Ϯ 1.9 mmol/l, aldosteroneϩactinomycin D EC 50 22.6 Ϯ 1.6 mmol/l, P Ͻ 0.001, Fig. 2A) . In control experiments, we found that actinomycin D did not affect CTGF in the absence of exogenous aldosterone (control EC 50 33.1 Ϯ 1.9 mmol/l, actinomycin D EC 50 32.6 Ϯ 1.2 mmol/l, Fig. 2B ).
To confirm that the effect of aldosterone on CTGF was nongenomic, we repeated the previous experiment, but instead of actinomycin D we used the protein synthesis inhibitor cycloheximide (10 Ϫ5 mol/l). Aldosterone also sensitized CTGF in the presence of cycloheximide (control EC 50 32.4 Ϯ 4.3 mmol/l, aldosterone ϩ cycloheximide EC 50 17.4 Ϯ 3.3 mmol/l, P Ͻ 0.001, Fig. 3A) . In control experiments, we found that cycloheximide does not affect CTGF in the absence of exogenous aldosterone (control EC 50 33.9 Ϯ 2.5 mmol/l, cycloheximide EC 50 33.8 Ϯ 2.0 mmol/l, Fig. 3B ). Thus, neither actinomycin D nor cycloheximide prevented the sensitization of CTGF by aldosterone, indicating a direct nongenomic effect of aldosterone on CTGF.
We then tested the effect of aldosterone on CTGF in the presence of the classical aldosterone antagonist eplerenone (previously thought to be selective for the intracellular MR, now recognized to also block the membrane-associated aldosterone receptor GPR30). Eplerenone (10 Ϫ5 mmol/l) added to the CNT perfusate prevented the sensitization of CTGF by aldosterone and the CTGF curve remained unchanged (control EC 50 33.2 Ϯ 1.7 mmol/l, aldosteroneϩeplerenone EC 50 33.5 Ϯ 1.3 mmol/l, Fig. 4A ). In control experiments, we found that eplerenone does not affect CTGF in the absence of exogenous aldosterone (control EC 50 31.2 Ϯ 2.2 mmol/l, eplerenone EC 50 33.2 Ϯ 2.2 mmol/l, Fig. 4B ).
To test whether GPR30 played a role in the sensitization of CTGF by aldosterone, we used the specific GPR30 blocker G36 (10 Ϫ5 mmol/l). In the presence of aldosterone, G36 attenuated CTGF (aldosterone alone EC 50 16.5 Ϯ 1.9 mmol/l, aldosterone ϩ G36 EC 50 29.0 Ϯ 2.1 mmol/l, P Ͻ 0.05, Fig. 5A ). These data indicate that GPR30 receptors mediate aldosteroneinduced sensitization of CTGF. To further confirm these results, we performed a control CTGF response, followed by Ϫ5 mol/l cycloheximide to the CNT perfusate did not prevent the sensitization of CTGF by aldosterone, suggesting that the effect of aldosterone on CTGF is not genomic. **P Ͻ 0.01; ***P Ͻ 0.001, control vs. aldosterone plus cycloheximide. B: cycloheximide alone did not affect CTGF in the absence of exogenous aldosterone.
coadministration of aldosterone and G36 during the second period. We found that G36 completely prevented aldosterone-induced sensitization of CTGF (control EC 50 30.0 Ϯ 0.1 mmol/l, aldosteroneϩG36 EC 50 30.5 Ϯ 1.5 mmol/l, Fig. 5B) . In control experiments, we found that G36 does not affect CTGF in the absence of exogenous aldosterone (control EC 50 28.9 Ϯ 1.2 mmol/l, G36 EC 50 28.1 Ϯ 1.7 mmol/l, Fig. 5C ). These data indicate that aldosterone sensitizes CTGF via GPR30.
Since basal CTGF is mediated by ENaC, we tested whether aldosterone-induced sensitization was also mediated by ENaC, by using the ENaC inhibitor benzamil (10 Ϫ6 mol/l). In the presence of aldosterone, benzamil added to the CNT perfusate only partially attenuated CTGF, indicating that the effect of aldosterone on CTGF is, at least in part, independent of ENaC (Fig. 6A) . Since NHE mediates some of the effects of aldosterone in the distal nephron in a nongenomic manner, we next tested whether NHE mediated the effect of aldosterone on CTGF. Addition of the NHE inhibitor dimethylamiloride (DMA; 10 Ϫ4 mol/l) together with benzamil to the CNT perfusate completely abolished both basal CTGF and its sensiti- Ϫ5 mol/l eplerenone to the CNT perfusate prevented the sensitization of CTGF by aldosterone, suggesting that this effect is mediated by either the mineralocorticoid receptor (MR) or G protein-coupled receptor 30 (GPR30). B: eplerenone alone did not affect CTGF in the absence of exogenous aldosterone.
Fig. 5. A: adding 10
Ϫ5 mol/l G36 to the CNT perfusate attenuated the sensitization of CTGF by aldosterone, suggesting that this effect is mediated, at least in part, by GPR30 (**P Ͻ 0.01; ***P Ͻ 0.001, aldosterone vs. aldosterone plus G36). B: adding G36 to the CNT perfusate completely prevented the sensitization of CTGF by aldosterone, indicating that this effect is mainly mediated by GPR30. C: G36 alone did not affect CTGF in the absence of exogenous aldosterone. zation by aldosterone (Fig. 6B) . These data suggest that the effect of aldosterone on CTGF is mediated, at least in part, by stimulation of sodium transport via NHE.
To elucidate whether aldosterone-induced sensitization was completely mediated by NHE, we combined aldosterone and DMA. Compared with control, aldosterone had no effect on CTGF when DMA was simultaneously perfused in the CNT, indicating that the effect of aldosterone on CTGF is completely dependent on NHE (Fig. 7A) . Finally, to determine whether NHE participates to any degree in basal CTGF, we studied the effect of DMA alone. In the absence of exogenous aldosterone, DMA was devoid of effect (Fig. 7B) , indicating that basal CTGF is not mediated by NHE.
DISCUSSION
We investigated the regulation of CTGF by intratubular aldosterone and found that addition of aldosterone to the CNT lumen sensitized CTGF. These effects were mediated by the aldosterone GPR30 receptors and did not require transcription or protein synthesis, indicating that the effect of aldosterone on CTGF is nongenomic.
Aldosterone plays a key role in renal control of Na ϩ , acid-base, and water balance by acting directly on the aldosterone-sensitive distal nephron which comprises the late distal convoluted tubule, the CNT, and the collecting duct (3, 12) . Historically it was assumed that aldosterone could only act via the classic genomic mechanism involving binding to the intracellular receptor, MR, thereby affecting transcription and protein synthesis (3) . In addition to its genomic effects, many experiments have shown that aldosterone can also elicit nongenomic responses by affecting signal transduction. These effects can be detected within seconds to few minutes and cannot be blocked by transcription and protein synthesis inhibitors, indicating the independence of these effects from the genomic effect of aldosterone (6, 40) . It is well-known that aldosterone is the main hormonal regulator of ENaC-dependent Na ϩ transport in the distal nephron (25, 38) . We reported that Fig. 6 . A: adding 10 Ϫ6 mol/l benzamil to the CNT perfusate did not prevent aldosterone from inducing CTGF, suggesting that this nongenomic effect of aldosterone is, at least in part, independent from ENaC (*P Ͻ 0.05, **P Ͻ 0.01, aldosterone vs. aldosterone plus benzamil; ##P Ͻ 0.01 vs. 0 NaCl). B: adding 10 Ϫ4 mol/l dimethylamiloride (DMA) and benzamil to the CNT perfusate completely abolished both basal CTGF and aldosterone-induced sensitization of CTGF (***P Ͻ 0.001, aldosterone vs. aldosterone plus DMA).
Fig. 7. A: adding 10
Ϫ4 mol/l DMA to the CNT perfusate completely prevented the sensitization of CTGF by aldosterone, indicating that this effect is mediated by the sodium/hydrogen exchanger. B: DMA alone did not affect CTGF in the absence of exogenous aldosterone, indicating that the sodium/hydrogen exchanger does not participate in basal CTGF. Na entry into the CNT via ENaC causes the attached Af-Art to dilate, a phenomenon we termed CTGF (34) . Furthermore, we showed that ANG II, which is known to increase ENaC activity, sensitizes CTGF (31, 34 ). Here, we tested the possibility that aldosterone may sensitize CTGF. Indeed, we found that when aldosterone was added to the CNT, the dilation of the Af-Art in response to CNT NaCl was augmented; in other words, aldosterone sensitized CTGF. Our results also indicated that the effects of aldosterone to sensitize CTGF responses are not genomic, because they were not prevented by the transcription inhibitor actinomycin D, or the translation inhibitor cycloheximide. Furthermore, two additional findings support the nongenomic nature of the effect we observed; first, the effect is very quick (within 10 min), and second, the effect is completely blocked by the GPR30 receptor blocker.
The plasma concentration for aldosterone ranges widely and it depends on hydration status, potassium, and ANG II levels. Similarly to other studies, in our experiments we used aldosterone in the concentration of 10 mmol/l (1, 12), which is somewhat higher than the physiological plasma levels. This allowed us to study the mechanism of aldosterone action when its downstream effectors are maximally activated. Our findings indicated the aldosterone's action on CTGF was nongenomic in nature since they were not blocked by actonomycin D or cycloheximide, used at concentrations similar or up to five times higher than those used in previous studies reporting blockade of genomic effects (23) . Also the fact that we used two drugs, one to block transcription and the other to block translation, makes our findings more reliable.
In the present study, we found that eplerenone completely blocked the effect of aldosterone on CTGF. Eplerenone, initially developed as a blocker of the intracellular MR, was recently found to also block the membrane-associated aldosterone receptor GPR30, thus these results indicate that the classical MR or the novel GPR30, or possibly both, is involved in aldosterone's action on CTGF. Nongenomic effects have been assumed to originate at the cell membrane, which is where most of the second messenger systems involved in rapid steroid actions are localized. Binding of aldosterone to membranes has been shown in porcine liver microsomes (27) as well as in human endothelial cells (41) . Although the protein responsible for the binding could not be identified, it showed the characteristics of a GTP-binding protein (40) . Despite all the efforts to identify the alternative receptor, no protein has been unequivocally validated. More recently, Gros et al. (17, 18) reported the involvement of GPR30 in the rapid effects of aldosterone in vascular smooth muscle cells and Brailoiu et al. (4) reported that GPR30 receptors mediated the effects of aldosterone in the nucleus ambiguous. GPR30 represents a heptahelical transmembrane protein acting as a G proteincoupled receptor (20) . GPR30 receptors are expressed in the renal tubules, particularly in the CNT (16, 29) .
Aldosterone can act rapidly via both GPR30 and classic MR; however, studies with MR antagonists such as spironolactone and eplerenone are confounded by the fact that these agents are also GPR30 antagonists (18) . These MR antagonists can block GPR30-mediated effects of aldosterone as well as the effects of a GPR30 agonist on vascular smooth muscle cell (18) . For this reason, we used a novel, specific antagonist of GPR30 receptors, namely G36. We found that G36 completely blocked the effect of aldosterone on CTGF; therefore, we concluded this rapid effect was due to GPR30. Our studies focused on the acute, nongenomic, effects of aldosterone, and we cannot rule out a genomic effect of classic MR in the long-term control of CTGF.
In addition to acting as a nongenomic receptor for aldosterone, GPR30 has been proposed to be an estrogen receptor (40) . However, the concentrations of aldosterone needed for activating GPR30 are in the physiologic range for this hormone, while supraphysiologic concentrations of estrogens are required to have a similar effect (40) . The fact that supraphysiologic concentrations of estrogens are needed to activate GPR30 also makes it unlikely that endogenous estrogens will participate in the regulation of CTGF. However, this possibility cannot be ruled out until further studies are conducted involving male and female animals.
We next posed the question of which sodium transporter in the CNT would be mediating the effect of aldosterone to sensitize CTGF. A natural candidate would be ENaC, since we repeatedly found that it mediates both basal CTGF and its sensitization by ANG II. However, although aldosterone is well-known to stimulate ENaC in a genomic manner, whether it can also do so in a nongenomic manner is not well-established. Aldosterone has been shown to stimulate subcellular translocation of ENaC in mouse cortical collecting duct cells in as little as 2 min (26), and also to activate sodium transport, as measured by patch-clamp, in a similar time frame (42) . However, the physiological relevance of these findings has been debated (14) . In our experiments, addition of the ENaC inhibitor was not able to completely block CTGF induced by aldosterone, indicating that the nongenomic effect of aldosterone to sensitize CTGF is, at least in part, independent of ENaC. The other sodium transporter that may play a role in the sensitization of CTGF by aldosterone is NHE, since it is present in the CNT and is known to respond to aldosterone in a nongenomic manner (13, 28) . We found that inhibition of NHE with DMA, when added to the CNT together with benzamil, completely abolished both basal CTGF and its sensitization by aldosterone. We also found that DMA can completely prevent the effect of aldosterone on CTGF, but it does not affect basal CTGF. Taken together, these data indicate that aldosterone sensitizes CTGF by acting on NHE, but in the absence of aldosterone basal CTGF is mediated by ENaC and not NHE.
Fu et al. (12) recently reported that aldosterone inhibits TGF, a mechanism that constricts the Af-Art. Since CTGF causes Af-Art dilation antagonizing the physiological action of TGF, the coordinated action of aldosterone to inhibit TGF and sensitize CTGF could act to further dilate the Af-Art and increase glomerular filtration.
There is now increasing evidence that aldosterone plays an important role in the pathogenesis and progression of renal diseases (9, 22) . We speculate that aldosterone may promote or aggravate the development of glomerulosclerosis by elevating glomerular capillary pressure through its dilator actions on Af-Art. Our results provided the first evidence that aldosterone can cause Af-Art dilation by sensitizing CTGF. This conclusion is in agreement with the clinical finding that glomerular capillary pressure was elevated in patients with primary aldosteronism (22) .
In many respects, the actions of ANG II and aldosterone are synergistic. We reported that ANG II sensitizes CTGF, likely by increasing ENaC activity in the CNT (31, 33) . Taken together, these findings suggest that CTGF is sensitized in pathophysiological conditions where the renin-angiotensin-aldosterone system is activated.
In summary, using an isolated perfused Af-Art with the CNT attached we found that intratubular aldosterone augmented CTGF response. The addition of actinomycin D and cycloheximide did not influence the effect of aldosterone on CTGF. Eplerenone and G36 completely blocked the effect of aldosterone. We conclude that aldosterone sensitized CTGF through a nongenomic action by acting on the aldosterone receptor GPR30.
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